







an Open Access Journal by MDPI

Why Use the Robotic System for the Esophageal Cancer in Minimally Invasive Surgery Era?—Current Status of Robotic Esophagectomy in the World—

Guest Editors:

Dr. Hiroyuki Daiko

Division of Esophageal Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan

Prof. Dr. Yin-Kai Chao

Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

Deadline for manuscript submissions:

closed (31 May 2024)

Message from the Guest Editors

Minimally Invasive Esophagectomy (MIE) in the left lateral and prone position was first reported in the 1990s. The prone position can provide direct viewing of the esophagus without organ compression and provides a stable and wide operative field, the anatomy of the mediastinum has become better understood in esophagectomy. Therefore, the transthoracic approach of MIE in the prone position has been widely accepted and has helped standardize esophagectomy. even in complicated operations. Moreover, MIE has already begun a paradigm shift toward robotic esophagectomy. This is because the robotic surgical system can facilitate precise surgical techniques by the robotic end-list function and provide magnified microanatomy by the robotic 3D high solution endoscopy. Robotic esophagectomy is still in the implementation phase overseas, and several robotic advantages over OPEN and thoracoscopic esophagectomy have been reported. Cancers will feature robotic-assisted MIE in the double 20. era and inform the current status of robotic esophagectomy in each country, but why use a robotic system for esophageal cancer in the era of minimally invasive surgery?













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us